ASAN FOUNDATION

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1989-06-23

Employees: 501

Market Cap: -

Website: https://ails.amc.seoul.kr

Clinical Trials

Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Drug: fentanyl

First Posted Date: 2015-03-30

Last Posted Date: 2015-12-02

Lead Sponsor: Asan Medical Center

Target Recruit Count: 111

Registration Number: NCT02402621

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes

Not Applicable

Completed

Conditions: Bladder Cancer

Interventions: Other: crystalloid
Other: colloid
Other: mannitol
Other: lasix

First Posted Date: 2015-02-27

Last Posted Date: 2015-12-30

Lead Sponsor: Asan Medical Center

Target Recruit Count: 64

Registration Number: NCT02373735

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

The Effect of ERAS on Pancreaticoduodenectomy

Not Applicable

Completed

Conditions: Periampullary Tumor

Interventions: Other: ERAS perioperative management

First Posted Date: 2015-02-26

Last Posted Date: 2017-06-09

Lead Sponsor: Asan Medical Center

Target Recruit Count: 276

Registration Number: NCT02372331

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation

Phase 3

Conditions: Kidney Transplantation

Interventions: Drug: Steroid
Drug: Bortezomib

First Posted Date: 2015-01-30

Last Posted Date: 2015-02-04

Lead Sponsor: Asan Medical Center

Target Recruit Count: 30

Registration Number: NCT02351427

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)

Phase 2

Conditions: Evidence of Liver Transplantation

Interventions: Drug: Eglandin

First Posted Date: 2015-01-29

Last Posted Date: 2018-07-06

Lead Sponsor: Asan Medical Center

Target Recruit Count: 76

Registration Number: NCT02350218

Locations: 🇰🇷
Korea, Republic of, Seoul, Korea, Republic of

Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Everolimus(afinitor)
Drug: Letrozole
Drug: Leuprolide(Lorelin Depot)

First Posted Date: 2015-01-26

Last Posted Date: 2020-07-30

Lead Sponsor: Asan Medical Center

Target Recruit Count: 137

Registration Number: NCT02344550

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)

Completed

Conditions: Chronic Interstitial Cystitis

First Posted Date: 2015-01-06

Last Posted Date: 2019-07-05

Lead Sponsor: Asan Medical Center

Target Recruit Count: 80

Registration Number: NCT02331472

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Asan medical center Institutional review board, Seoul, Korea, Republic of

Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)

Phase 2

Conditions: Hepatocellular Carcinoma
Metastasis

Interventions: Procedure: Conventional Transarterial Chemoembolization (TACE)
Drug: sorafenib

First Posted Date: 2014-12-08

Last Posted Date: 2017-12-18

Lead Sponsor: Asan Medical Center

Target Recruit Count: 55

Registration Number: NCT02311205

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Bicarbonate in Patients With Out-of-hospital Cardiac Arrest

Phase 2

Completed

Conditions: Cardiac Arrest
Metabolic Acidosis

Interventions: Drug: Normal saline
Drug: Sodium bicarbonate

First Posted Date: 2014-12-01

Last Posted Date: 2022-03-25

Lead Sponsor: Asan Medical Center

Target Recruit Count: 50

Registration Number: NCT02303548

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

Phase 1

Withdrawn

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: dovitinib plus imatinib

First Posted Date: 2014-10-20

Last Posted Date: 2015-08-04

Lead Sponsor: Asan Medical Center

Registration Number: NCT02268435

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy